According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
Separately, Cowen downgraded Corindus Vascular Robotics from an outperform rating to a market perform rating and lifted their price target for the stock from $4.00 to $4.28 in a research note on Thursday, August 8th.
NYSEAMERICAN:CVRS opened at $4.27 on Tuesday. Corindus Vascular Robotics has a one year low of $0.78 and a one year high of $4.30.
Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The company had revenue of $4.58 million during the quarter, compared to analyst estimates of $4.10 million.
A number of hedge funds have recently modified their holdings of CVRS. Jane Street Group LLC acquired a new position in Corindus Vascular Robotics in the fourth quarter valued at approximately $36,000. Steward Partners Investment Advisory LLC raised its holdings in shares of Corindus Vascular Robotics by 36.4% during the second quarter. Steward Partners Investment Advisory LLC now owns 15,000 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 4,000 shares during the last quarter. Tealwood Asset Management Inc. raised its holdings in shares of Corindus Vascular Robotics by 50.0% during the second quarter. Tealwood Asset Management Inc. now owns 15,000 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 5,000 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Corindus Vascular Robotics during the second quarter valued at approximately $58,000. Finally, Weiss Asset Management LP bought a new stake in shares of Corindus Vascular Robotics during the first quarter valued at approximately $65,000.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.
Featured Story: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.